---
title: "Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS"
euct_id: 2025-523872-22-00
phase: Phase 1
status: Recruiting
sponsor: Nrg Therapeutics Limited
canonical_url: "https://parkinsonspathways.com/trials/eu/2025-523872-22-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2025-523872-22-00"
ctis_last_updated: "2026-03-11T02:41:29.744168449"
source: EU Clinical Trials Information System (CTIS)
---
# Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS

**EU CT Number:** [2025-523872-22-00](https://euclinicaltrials.eu/ctis-public/view/2025-523872-22-00)

## Key Facts

- **Phase:** Phase 1
- **Status:** Recruiting
- **Sponsor:** Nrg Therapeutics Limited
- **Start Date:** 2025-11-17
- **Completion Date:** 2026-11-03
- **Conditions:** Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Centre for Human Drug Research, Leiden, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)
Age groups: elderly 65+, adults 18-64
Sex: male, female
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2025-523872-22-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2025-523872-22-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2025-523872-22-00*